Literature DB >> 28363855

Planetary ball milling and supercritical fluid technology as a way to enhance dissolution of bicalutamide.

Joanna Szafraniec1, Agata Antosik2, Justyna Knapik-Kowalczuk3, Mateusz Kurek2, Karolina Syrek4, Krzysztof Chmiel3, Marian Paluch3, Renata Jachowicz2.   

Abstract

Dissolution of bicalutamide processed with polyvinylpyrrolidone by either supercritical carbon dioxide or ball milling has been investigated. Various compositions as well as process parameters were used to obtain binary systems of the drug with the carrier. Thermal analysis and powder X-ray diffractometry confirmed amorphization of bicalutamide mechanically activated by ball milling and the decrease in crystallinity of the supercritical carbon dioxide-treated drug. Both methods led to reduction of particles size what was confirmed by scanning electron microscopy and laser diffraction measurements. Moreover, the effect of micronisation was found to depend on the parameters of applied process. Fourier transform infrared spectroscopy revealed the appearance of intermolecular interactions between drug and carrier molecules that play an important role in the stabilization of amorphous form of the active compound. Changes in crystal structure combined with reduced size of particles of bicalutamide dispersed within polymer matrix were found to improve dissolution of bicalutamide by 4 to 10-fold in comparison to untreated drug. It is of particular importance as poor dissolution profiles are considered to be the major limitation in bioavailability of the drug.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bicalutamide PVP; Dissolution; Planetary ball milling; Solid dispersion; Supercritical CO(2)

Mesh:

Substances:

Year:  2017        PMID: 28363855     DOI: 10.1016/j.ijpharm.2017.03.078

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Optimization of a combined wet milling process in order to produce poly(vinyl alcohol) stabilized nanosuspension.

Authors:  Csaba Bartos; Orsolya Jójárt-Laczkovich; Gábor Katona; Mária Budai-Szűcs; Rita Ambrus; Alexandra Bocsik; Ilona Gróf; Mária Anna Deli; Piroska Szabó-Révész
Journal:  Drug Des Devel Ther       Date:  2018-05-31       Impact factor: 4.162

2.  Studies on the Vitrified and Cryomilled Bosentan.

Authors:  Aldona Minecka; Krzysztof Chmiel; Karolina Jurkiewicz; Barbara Hachuła; Rafał Łunio; Daniel Żakowiecki; Kinga Hyla; Bartłomiej Milanowski; Kajetan Koperwas; Kamil Kamiński; Marian Paluch; Ewa Kamińska
Journal:  Mol Pharm       Date:  2021-12-01       Impact factor: 4.939

3.  Another Move towards Bicalutamide Dissolution and Permeability Improvement with Acetylated β-Cyclodextrin Solid Dispersion.

Authors:  Tatyana V Volkova; Olga R Simonova; German L Perlovich
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

4.  Compression-Induced Phase Transitions of Bicalutamide.

Authors:  Joanna Szafraniec-Szczęsny; Agata Antosik-Rogóż; Justyna Knapik-Kowalczuk; Mateusz Kurek; Ewa Szefer; Karolina Gawlak; Krzysztof Chmiel; Sebastian Peralta; Krzysztof Niwiński; Krzysztof Pielichowski; Marian Paluch; Renata Jachowicz
Journal:  Pharmaceutics       Date:  2020-05-09       Impact factor: 6.321

5.  Molecular Disorder of Bicalutamide-Amorphous Solid Dispersions Obtained by Solvent Methods.

Authors:  Joanna Szafraniec; Agata Antosik; Justyna Knapik-Kowalczuk; Karolina Gawlak; Mateusz Kurek; Jakub Szlęk; Witold Jamróz; Marian Paluch; Renata Jachowicz
Journal:  Pharmaceutics       Date:  2018-10-18       Impact factor: 6.321

6.  Data-Driven Modeling of the Bicalutamide Dissolution from Powder Systems.

Authors:  Aleksander Mendyk; Adam Pacławski; Joanna Szafraniec-Szczęsny; Agata Antosik; Witold Jamróz; Marian Paluch; Renata Jachowicz
Journal:  AAPS PharmSciTech       Date:  2020-03-31       Impact factor: 3.246

7.  Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.

Authors:  Justyna Knapik-Kowalczuk; Daniel Kramarczyk; Karolina Jurkiewicz; Krzysztof Chmiel; Marian Paluch
Journal:  Mol Pharm       Date:  2021-08-22       Impact factor: 4.939

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.